<DOC>
	<DOCNO>NCT01167244</DOCNO>
	<brief_summary>The purpose study observe improvement overall response rate NSCLC subject treat gefitinib erlotinib genotypically EGFR mutation positive prior response .</brief_summary>
	<brief_title>Trial BMS-690514 Non-Small Cell Lung Cancer Subjects Who Have Been Treated With Gefitinib Erlotinib Are Genotypically EGFR Mutation Positive Who Have Had Prior Response</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Recurrent , metastatic progressive NSCLC without indication radiotherapy . Subjects must : Pathologically confirm NSCLC Previously receive treatment single agent Gefitinib Erlotinib complete treatment least 2 week prior study entry Any one following : A tumor harbor EGFR mutation Objective clinical benefit treatment Gefitinib Erlotinib define either document confirm partial complete response ( RECIST WHO ) , significant durable ( ≥ 6 month ) clinical benefit ( stable disease define RECIST WHO ) Progression NSCLC continuous treatment gefitinib erlotinib note CT/MRI increase disease confirm partial complete response evidence ≥ 6 month SD within 3 month study enrollment Symptomatic brain metastasis History TIA , CVA , thrombotic/thromboembolic event ( within last 6 month ) History hemoptysis great 10 mL/day within last 30 day Uncontrolled significant cardiovascular disease History uncontrolled diarrhea , Crohn 's disease ulcerative colitis Inability swallow tablet , untreated malabsorption GI surgery result inability absorb protocol therapy Women unwilling avoid pregnancy use adequate contraception History allergy adverse drug reaction gefitinib erlotinib</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>